Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | JAK1 | P23458 | 1/20 | 0.52 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.45 |
| ▸ | STS | P08842 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25339310 | 0.92 | SMN1; SMN2 (0.48) | SIGMAR1JAK2JAK1USP30GPR119 | |
| SCHEMBL13963235 | 0.92 | SMN1; SMN2 (0.48) | SIGMAR1JAK2JAK1USP30GPR119 | |
| SCHEMBL6071087 | 0.92 | SMN1; SMN2 (0.48) | SIGMAR1JAK2JAK1USP30GPR119 | |
| SCHEMBL13963237 | 0.92 | SMN1; SMN2 (0.48) | SIGMAR1JAK2JAK1USP30GPR119 | |
| SCHEMBL13963234 | 0.92 | SMN1; SMN2 (0.48) | SIGMAR1JAK2JAK1USP30GPR119 | |
| SCHEMBL30194981 | 0.91 | SIGMAR1 (0.49) | SIGMAR1JAK2JAK1USP30STS | |
| SCHEMBL19212453 | 0.91 | SIGMAR1 (0.49) | SIGMAR1JAK2JAK1USP30STS | |
| SCHEMBL27427346 | 0.91 | SIGMAR1 (0.49) | SIGMAR1JAK2JAK1USP30STS | |
| SCHEMBL3355474 | 0.88 | JAK2 (0.52) | JAK2JAK1USP30GPR119STS | |
| SCHEMBL3352325 | 0.88 | JAK2 (0.52) | JAK2JAK1USP30GPR119STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240342292-A1 | Compounds for the Degradation of EGFR Kinase | BEIGENE SWITZERLAND GMBH (CH) | 2024-10-17 | — | — | US | disclosed |
| EP-4444724-A1 | COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE | BeiGene Switzerland GmbH (CH) | 2024-10-16 | — | — | EP | disclosed |
| CN-118488958-A | Compounds for degrading EGFR kinase | 百济神州有限公司 | 2024-08-13 | — | — | CN | disclosed |
| WO-2023098656-A1 | COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE | BEIGENE, LTD. (GB) | 2023-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240342292-A1 | Compounds for the Degradation of EGFR Kinase | EGFR, ERBB2, ERBB3 | SIGMAR1 3498/4885JAK2 760/4885JAK1 865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.